Celltrion · 투자판단관련주요경영사항 (CTP13 SC(짐펜트라) 유럽 임상 3상 시험계획 승인(Part1&2) (류마티스 관절염 환자))
Celltrion reported that the European Medicines Agency (EMA) approved Part 1 and Part 2 of its Phase 3 clinical trial application for CT-P13 SC (Zymfentra) at the same time. The patients have moderately to severely active rheumatoid arthritis. The randomized, placebo-controlled, double-blind trial will enroll 296 subjects for a 52-week treatment period. The primary endpoint is superiority over placebo in ACR50 clinical response at Week 12.
Material Management Matters Relevant to Investment Decisions
| 1. Title | Approval of European Phase 3 Clinical Trial Application (Part 1 & 2) for CT-P13 SC (Zymfentra) (Patients with Rheumatoid Arthritis) | |
| 2. Key Details | ※ Investment Caution: Statistically, the probability that an investigational drug receives final approval as a medicinal product is known to be about 10%. The clinical trial and marketing authorization processes may produce results that do not meet expectations. As a result, the Company may change or abandon its commercialization plans. Investors should comprehensively consider the investment risks disclosed in ad-hoc disclosures, business reports, and other filings, and invest with caution. 1) Clinical trial title: <br><br> - A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Injection of CT-P13 (CT-P13 SC) in Patients with Moderately to Severely Active Rheumatoid Arthritis 2) Clinical trial phase: <br><br> - Global Phase 3 clinical trial 3) Target disease (indication): <br><br> - Rheumatoid Arthritis (RA) 4) Clinical trial application date, approval date, and authority: <br><br> - Application date: 2026-07-24 (local time) <br><br> - Approval date: 2026-10-30 (local time) <br><br> - Authority receiving the application: European Medicines Agency (EMA) 5) Clinical trial registration number: <br><br> - EU CT number: 2026-526538-15 6) Clinical trial objective: <br><br> - To demonstrate the superiority of CT P13 SC over placebo in terms of efficacy, as determined by clinical response according to ACR50 at Week 12. 7) Clinical trial method: <br><br> - Subjects: 296 <br><br> - Trial period: 52-week treatment period <br><br> - Trial design: Randomized, placebo-controlled, double-blind, parallel-group, Phase 3 clinical trial 8) Future plans: <br><br> - CT-P13 SC (Zymfentra) is the subcutaneous formulation of Remsima IV, an infliximab biosimilar. The Company developed it to improve patient dosing convenience and to provide more treatment opportunities. <br><br> - CT-P13 SC completed Phase 3 clinical trials in adult patients with ulcerative colitis and Crohn's disease, and obtained marketing authorization in multiple countries, including the United States and Europe. The Company expects that this Phase 3 rheumatoid arthritis trial will make it possible to provide treatment opportunities to more patients, in addition to the adult ulcerative colitis and Crohn's disease indications. 9) Other matters: <br><br> - Due to the revision of the EU Clinical Trials Regulation, from 2023-01-31 the European clinical trial application/approval procedure has been divided into Part 1 (assessment of clinical design and research methods) and Part 2 (assessment of clinical sites and conduct). A clinical trial can proceed only after both Part 1 and Part 2 receive final approval. Please note that this disclosure concerns the simultaneous approval of Part 1 and Part 2 of the European Phase 3 clinical trial application. | |
| 3. Date of board of directors resolution (decision) or date of fact confirmation | 2026-11-02 | |
| - Attendance of independent (outside) directors* | Present (persons) | - |
| Absent (persons) | - | |
| - Attendance of auditor (audit committee member who is not an independent (outside) director) | - | |
| 4. Other important matters relevant to investment decisions | ||
| - The above date of fact confirmation is the date on which the Company confirmed the approval of the clinical trial application in CTIS (Clinical Trial Information System). - Please note that this disclosure concerns the simultaneous approval of Part 1 and Part 2 of the European Phase 3 clinical trial application. - The Company plans to use the contents of this disclosure in its future press releases and IR materials. | ||
| ※ Related disclosure | 2026-07-24 Material Management Matters Relevant to Investment Decisions (Application for European Phase 3 Clinical Trial (Part 1 & 2) for CTP13 SC (Zymfentra) (Patients with Rheumatoid Arthritis)) | |